Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for biomarkers to personalize endometrial cancer immunotherapy

NCT ID NCT07374809

Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will analyze tumor samples from 50 women with advanced or recurrent endometrial cancer to find biological markers that predict whether immunotherapy will work. Researchers will examine the tumor's DNA, epigenetics, and surrounding environment. The goal is to better understand why some patients respond to treatment and others do not, paving the way for more personalized care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients ≥ 18 years old. * Histologically confirmed epithelial endometrial carcinoma (endometrioid, serous, clear cell, mixed, or carcinosarcoma). * Advanced (stage III-IV) or recurrent disease, eligible for surgery or biopsy as part of the therapeutic plan. * Availability of fresh-frozen or OCT-embedded tumor tissue obtained at surgery/biopsy and stored in the IEO Biobank. * Mismatch-repair-deficient (dMMR) or -proficient (pMMR) molecular subtype (when available). * Written informed consent for participation and use of biological material for translational research purposes. Exclusion Criteria: * Mesenchymal tumors or epithelial tumors of non-endometrial origin (e.g., ovarian, cervical). * Prior systemic treatment with immune checkpoint inhibitors for other malignancies. * Insufficient or poor-quality tumor tissue available for molecular analyses. * Active or uncontrolled infection with HIV, HBV, or HCV. * Any condition that, in the investigator's judgment, would compromise patient safety or study integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DMMR cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DMMR cancer Endometrial carcinoma (EC) PMMR

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Europeo di Oncologa

    Milan, Lombardy, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.